First patient in GLORY-2 study for mazdutide 9mg in Chinese adults with obesityThe first participant has been successfully dosed in Innovent Biologics’ Phase 3 clinical trial (GLORY-2) of higher dose 9mg mazdutide, a...
Journal Watch 20/12/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Mazdutide 9mg results in mean percent change in body weight of 15.4% at 24 weeksInnovent Biologics has revealed its phase 2 clinical study of higher dose (9mg) mazdutide in Chinese adults with obesity achieved the...
Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesityInnovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...
High-dose mazdutide may offer bariatric surgery-equivalent weight lossInnovent Biologics has announced that the outcomes of high-dose cohorts in a phase 1 clinical trial of mazdutide (IBI362) - a...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure1 day ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity1 day ago